A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
A legfontosabb adatok
- Hol
- Shreveport (Egyesült Államok)A helyszín megnézése
- Fázis
- 2. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Forrás: NCT07867938: ki vehet részt
Helyszínek itt: Egyesült Államok
- Care Access Research Llc (Site 2725)Shreveport, Egyesült ÁllamokContact: Study CoordinatorRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Merck Sharp & Dohme LLC
- Azonosító
- NCT07867938EU 2025-524270-42-00
- A regiszteradat frissítve
- 2026. november 9.
- Eredeti leírás
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).A teljes eredeti leírásKevesebb
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).
This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.
Bevonási feltételek: The main inclusion criteria include but are not limited to the following:; Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy; Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening; Has active PS within 3 months before Screening.
Kizáró feltételek: Is receiving treatment for pulmonary hypertension; Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment; Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening; Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a clinically significant electrocardiogram abnormality that requires evaluation or intervention; Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome; Has active tuberculosis (TB) or history of active TB; Has any condition that may interfere with the ability to adhere to oral corticosteroid therapy or taper; Has a history of cancer and is disease free for <5 years; The main exclusion criteria include but are not limited to the following:.